8-K: Quantum-Si Reports Q3 2025 Results, Proteus On Track

Quantum-Si Incorporated announced third quarter 2025 financial results, reporting $552,000 in revenue and successful sequencing on a prototype Proteus system, with the development program remaining on track.

Summary

• Reported revenue of $552,000 for the third quarter of 2025, and $2.0 million for the nine months ended September 30, 2025.
• Gross profit was $194,000 and gross margin was 35% for Q3 2025; for the nine months, gross profit was $1.0 million and gross margin was 52%.
• Total operating expenses were $40.0 million in Q3 2025, compared to $28.5 million in the prior year, including $15.4 million in one-time charges for legacy litigation settlements and lease termination expense.
• Adjusted total operating expenses were $21.4 million in Q3 2025, down from $26.0 million in the prior year.
• Net loss was $35.7 million in Q3 2025, compared to a net loss of $25.3 million in the prior year.
• Adjusted EBITDA was negative $20.1 million in Q3 2025, an improvement from negative $24.5 million in the prior year.
• Achieved successful sequencing runs on a prototype Proteus system, with the development program remaining on track for a second half of 2026 launch.
• Launched version 4 Sequencing Kit in early September and the version 3 Library Prep Kit for low input samples remains on track for launch before year-end 2025.
• The instrument placement program has shown early success, increasing access to academic customers despite NIH funding uncertainty.
• Cash and cash equivalents and investments in marketable securities totaled $230.5 million as of September 30, 2025, anticipated to fund operations into the second quarter of 2028.

Sentiment

Score: 6

Explanation: While GAAP financial results show a decline in revenue and increased net loss, largely due to one-time charges, the company demonstrated progress on key development milestones, including successful sequencing on a prototype Proteus system and on-track launches for new kits. Adjusted operating expenses and EBITDA improved, and the company maintains a strong cash position expected to last into Q2 2028. The strategic instrument placement program is also showing early success.

Positives

• Successful sequencing runs on a prototype Proteus system, keeping the development program on track for a second half of 2026 launch.
• Adjusted total operating expenses decreased to $21.4 million in Q3 2025 from $26.0 million in Q3 2024, demonstrating tight expense management.
• Adjusted EBITDA improved to negative $20.1 million in Q3 2025 from negative $24.5 million in Q3 2024.
• Cash and investments of $230.5 million are expected to fund operations into the second quarter of 2028, providing a strong financial runway.
• Successfully launched the version 4 Sequencing Kit in early September.
• The version 3 Library Prep Kit for low input samples remains on track for launch before year-end 2025.
• The instrument placement program is showing early success, increasing access for academic customers and driving greater awareness and potential consumable volume.

Negatives

• Revenue decreased to $552,000 in Q3 2025 from $787,000 in Q3 2024.
• Gross profit decreased to $194,000 in Q3 2025 from $367,000 in Q3 2024, with gross margin declining to 35% from 46.6%.
• Total operating expenses increased significantly to $40.0 million in Q3 2025 from $28.5 million in Q3 2024, primarily due to one-time charges.
• Net loss increased to $35.7 million in Q3 2025 from $25.3 million in Q3 2024.
• Included in Q3 2025 operating expenses and net loss are two one-time charges totaling $15.4 million associated with legacy litigation settlements and lease termination expense.

Risks

• Inability to maintain the listing of Class A common stock on The Nasdaq Stock Market.
• Ability to grow and manage growth profitably and retain key employees.
• Ongoing leadership transitions within the company.
• Changes in applicable laws or regulations.
• Ability to raise financing in the future.
• Success, cost, and timing of product development and commercialization activities, including the use and benefit of artificial intelligence.
• Commercialization and adoption of existing products and the success of any future products.
• Potential attributes and benefits of commercialized Platinum protein sequencing instruments and kits and other future products.
• Ability to obtain and maintain regulatory approval for products, and any related restrictions and limitations.
• Ability to identify, in-license, or acquire additional technology.
• Ability to maintain existing lease, license, manufacture, and supply agreements.
• Ability to compete with other companies in proteomic analysis, many of which have greater financial and marketing resources.
• Size and growth potential of the markets for products and services, and ability to serve those markets.
• Estimates regarding future expenses, future revenue, capital requirements, and needs for additional financing.
• Overall financial performance.

Future Outlook

The company anticipates its cash and investments of $230.5 million will carry operations into the second quarter of 2028. The Proteus platform development program remains on track for a second half of 2026 launch. The version 3 Library Prep Kit for low input samples is expected to launch before year-end 2025. The company plans to continue using a mix of instrument acquisition options to increase awareness and build momentum for the Proteus platform.

Management Comments

• "During the third quarter we launched a range of instrument acquisition options to help overcome the headwinds associated with the NIH funding uncertainty and our results thus far have been promising." Jeff Hawkins, President and Chief Executive Officer.
• "Our instrument placement program allowed us to deploy our sequencing technology to several new academic customers who were previously unable to acquire the platform in the current capital spending environment." Jeff Hawkins.
• "Increasing the number of customers utilizing our technology is expected to help us fulfill the goals of driving greater awareness, enabling studies that will drive publications, and capturing consumable volume and revenue." Jeff Hawkins.
• "As we move forward, we will continue to use a mix of instrument acquisition options to increase the awareness of our technology and build momentum towards our future Proteus platform launch." Jeff Hawkins.
• "On the development front, we continue to achieve goals that we have set for ourselves, including delivering on the version 4 Sequencing Kit launch in early September and remaining on track for our version 3 Library Prep Kit launch before year end." Jeff Hawkins.
• "Finally, we achieved a major milestone by demonstrating successful sequencing on a prototype Proteus system and remain on track to deliver this transformative platform in second half of 2026." Jeff Hawkins.
• "We will have updates on all these initiatives, as well as a deeper dive into our Proteus platform development program and future roadmap at our Investor and Analyst Day on November 19th." Jeff Hawkins.

Industry Context

The company operates in the proteomics technology sector, aiming to redefine protein analysis through single-molecule detection. The mention of 'NIH funding uncertainty' suggests a challenging funding environment for academic research, which impacts capital equipment sales. The company's strategy of offering instrument acquisition options and placement programs is a direct response to these industry headwinds, aiming to broaden adoption and drive future consumable revenue. The development of the Proteus platform positions them for future growth in this evolving field, seeking to simplify, accelerate, and enhance protein analysis.

Legal Proceedings

• Settled two legacy litigation cases during the third quarter of 2025, resulting in a total charge of $15.4 million.

Stakeholder Impact

• Shareholders: Mixed financial results (lower revenue, higher net loss) but positive operational updates (Proteus progress, kit launches, cash runway) could lead to varied sentiment. The Investor Day is an opportunity for more detailed insights.
• Customers (Academic): The instrument placement program increases access to Quantum-Si's technology, potentially benefiting academic researchers by overcoming funding hurdles.
• Employees: Continued funding of the Proteus development program and tight management of operating expenses suggest a focus on core activities, but 'ongoing leadership transitions' are mentioned as a risk in forward-looking statements, which could imply some instability.

Next Steps

• Launch of version 3 Library Prep Kit for low input samples before year-end 2025.
• Host an Investor and Analyst Day on Wednesday, November 19, 2025, to provide updates on initiatives, a deeper dive into the Proteus platform development, and future roadmap.
• Continue to use a mix of instrument acquisition options to increase awareness of the technology and build momentum towards the future Proteus platform launch.
• Deliver the transformative Proteus platform in the second half of 2026.

Key Dates

Recommendation

While the GAAP financial performance for Q3 2025 shows a decline in revenue and an increased net loss, largely impacted by one-time legal settlement and lease termination expenses, the company has made significant operational progress. The successful sequencing on a prototype Proteus system and the on-track development for a H2 2026 launch are strong indicators of future potential in a transformative technology. The improved adjusted EBITDA and a robust cash runway into Q2 2028 provide financial stability. However, the current commercialization phase shows headwinds, as evidenced by the revenue dip and the need for instrument placement programs. An investor would likely hold, awaiting further clarity on commercial traction and the detailed roadmap for the Proteus platform at the upcoming Investor Day, balancing current financial challenges against long-term technological promise.

Keywords

Proteomics, Protein Analysis, Single-Molecule Detection, Sequencing Technology, Platinum Pro, Proteus Platform, Biotechnology, Life Sciences, Financial Results, Q3 2025, Quantum-Si, QSI